Conducting drug research

CPD employees have prepared a number of protocols and other documents necessary to obtain permission from the Ministry of Health of the Russian Federation to conduct drug research.

Clinical studies

• Phase I of the original preparation of the Russian manufacturer, which has pronounced sorption and detoxification properties;
• bioequivalence of a drug from the group of adaptogenic drugs with immunostimulating and adaptogenic effects;
• bioequivalence of a metabolic agent, a precursor of ATP, which has antihypoxic, metabolic and antiarrhythmic effects, used in the treatment of cardiology (myocardial infarction, coronary insufficiency, cardiac arrhythmias, congenital and acquired heart defects, rheumatic heart defects);
• bioequivalence of an antianginal agent used in the treatment of angina pectoris and chronic heart failure;
• bioequivalence of the drug used in the treatment of migraine (selective agonist of 5-hydroxytryptamine 1D receptors);
• bioequivalence of an opioid analgesic, an agonist of opioid receptors, used in the treatment of severe pain syndrome in severe diseases and injuries, including malignant neoplasms, myocardial infarction, in preparation for surgery and in the postoperative period.